216 related articles for article (PubMed ID: 26526283)
1. Complex relationship between sex hormones, insulin resistance and leptin in men with and without prostatic disease.
Grosman H; Fabre B; Lopez M; Scorticati C; Lopez Silva M; Mesch V; Mazza O; Berg G
Aging Male; 2016; 19(1):40-5. PubMed ID: 26526283
[TBL] [Abstract][Full Text] [Related]
2. Lipoproteins, sex hormones and inflammatory markers in association with prostate cancer.
Grosman H; Fabre B; Mesch V; Lopez MA; Schreier L; Mazza O; Berg G
Aging Male; 2010 Jun; 13(2):87-92. PubMed ID: 19921964
[TBL] [Abstract][Full Text] [Related]
3. Serum sex hormones and measures of benign prostatic hyperplasia.
Roberts RO; Jacobson DJ; Rhodes T; Klee GG; Leiber MM; Jacobsen SJ
Prostate; 2004 Oct; 61(2):124-31. PubMed ID: 15305335
[TBL] [Abstract][Full Text] [Related]
4. Insulin-like growth factor (IGF)-I, IGF binding protein-3, and prostate cancer: correlation with Gleason score.
Correa LL; Neto LV; Lima GA; Gabrich R; Miranda LC; Gadelha MR
Int Braz J Urol; 2015; 41(1):110-5. PubMed ID: 25928516
[TBL] [Abstract][Full Text] [Related]
5. Sex steroids in serum and prostatic tissue of human cancerous prostate (STERKPROSER trial).
Meunier ME; Neuzillet Y; Raynaud JP; Radulescu C; Ghoneim T; Fiet J; Giton F; Rouanne M; Dreyfus JF; Lebret T; Botto H
Prostate; 2019 Feb; 79(3):272-280. PubMed ID: 30370569
[TBL] [Abstract][Full Text] [Related]
6. Analysis of relations between serum levels of epitestosterone, estradiol, testosterone, IGF-1 and prostatic specific antigen in men with benign prostatic hyperplasia and carcinoma of the prostate.
Hill M; Bílek R; Safarík L; Stárka L
Physiol Res; 2000; 49 Suppl 1():S113-8. PubMed ID: 10984080
[TBL] [Abstract][Full Text] [Related]
7. Clinical and metabolic implications of obesity in prostate cancer: is testosterone a missing link?
Duarte MF; Luis C; Baylina P; Faria MI; Fernandes R; La Fuente JM
Aging Male; 2019 Dec; 22(4):228-240. PubMed ID: 30354924
[No Abstract] [Full Text] [Related]
8. Hormone concentration, metabolic disorders and immunoexpression of androgen and estrogen-alpha receptors in men with benign prostatic hyperplasia and testosterone deficiency syndrome.
Ryl A; Rotter I; Slojewski M; Dolegowska B; Grabowska M; Baranowska-Bosiacka I; Laszczynska M
Folia Histochem Cytobiol; 2015; 53(3):227-35. PubMed ID: 26400665
[TBL] [Abstract][Full Text] [Related]
9. Insulin-like growth factor I (IGF-I) and IGF-binding protein-3 in benign prostatic hyperplasia and prostate cancer.
Khosravi J; Diamandi A; Mistry J; Scorilas A
J Clin Endocrinol Metab; 2001 Feb; 86(2):694-9. PubMed ID: 11158033
[TBL] [Abstract][Full Text] [Related]
10. IGF-II serum levels increase discrimination between benign prostatic hyperplasia and prostate cancer and improve the predictive value of PSA in clinical staging.
Trojan L; Bode C; Weiss C; Mayer D; Grobholz R; Alken P; Michel MS
Eur Urol; 2006 Feb; 49(2):286-92; discussion 292. PubMed ID: 16386354
[TBL] [Abstract][Full Text] [Related]
11. Serum adipocytokine levels in prostate cancer patients.
Arisan ED; Arisan S; Atis G; Palavan-Unsal N; Ergenekon E
Urol Int; 2009; 82(2):203-8. PubMed ID: 19322011
[TBL] [Abstract][Full Text] [Related]
12. Circulating Levels of Omentin, Leptin, VEGF, and HGF and Their Clinical Relevance with PSA Marker in Prostate Cancer.
Fryczkowski M; Bułdak RJ; Hejmo T; Kukla M; Żwirska-Korczala K
Dis Markers; 2018; 2018():3852401. PubMed ID: 30186533
[TBL] [Abstract][Full Text] [Related]
13. Comparison of chromogranin A, insulin-like growth factor 1 and prostate-specific antigen serum markers in prostate adenocarcinoma and benign prostatic hyperplasia.
Sciarra A; Gentile V; Monti S; Dattilo C; Autran Gomez A; Salciccia S; Pannunzi LP; Toscano V; Di Silverio F
Urol Int; 2008; 80(1):68-73. PubMed ID: 18204237
[TBL] [Abstract][Full Text] [Related]
14. Elevated insulin and reduced insulin like growth factor binding protein-3/prostate specific antigen ratio with increase in prostate size in Benign Prostatic Hyperplasia.
Sreenivasulu K; Nandeesha H; Dorairajan LN; Rajappa M; Vinayagam V
Clin Chim Acta; 2017 Jun; 469():37-41. PubMed ID: 28300542
[TBL] [Abstract][Full Text] [Related]
15. Calculated fast-growing benign prostatic hyperplasia--a risk factor for developing clinical prostate cancer.
Hammarsten J; Högstedt B
Scand J Urol Nephrol; 2002; 36(5):330-8. PubMed ID: 12487736
[TBL] [Abstract][Full Text] [Related]
16. Comparison between selected hormone and protein levels in serum and prostate tissue homogenates in men with benign prostatic hyperplasia and metabolic disorders.
Grzesiak K; Rył A; Baranowska-Bosiacka I; Rotter I; Dołęgowska B; Słojewski M; Sipak-Szmigiel O; Ratajczak W; Lubkowska A; Metryka E; Piasecka M; Laszczyńska M
Clin Interv Aging; 2018; 13():1375-1382. PubMed ID: 30122909
[TBL] [Abstract][Full Text] [Related]
17. Insulin-like growth factor 1 in relation to prostate cancer and benign prostatic hyperplasia.
Mantzoros CS; Tzonou A; Signorello LB; Stampfer M; Trichopoulos D; Adami HO
Br J Cancer; 1997; 76(9):1115-8. PubMed ID: 9365156
[TBL] [Abstract][Full Text] [Related]
18. Leptin in relation to prostate cancer and benign prostatic hyperplasia.
Lagiou P; Signorello LB; Trichopoulos D; Tzonou A; Trichopoulou A; Mantzoros CS
Int J Cancer; 1998 Mar; 76(1):25-8. PubMed ID: 9533757
[TBL] [Abstract][Full Text] [Related]
19. Insulin-like growth factor-binding protein-2 in patients with prostate carcinoma and benign prostatic hyperplasia.
Ho PJ; Baxter RC
Clin Endocrinol (Oxf); 1997 Mar; 46(3):333-42. PubMed ID: 9156044
[TBL] [Abstract][Full Text] [Related]
20. Interrelationships between plasma testosterone, SHBG, IGF-I, insulin and leptin in prostate cancer cases and controls.
Kaaks R; Lukanova A; Rinaldi S; Biessy C; Söderberg S; Olsson T; Stenman UH; Riboli E; Hallmans G; Stattin P
Eur J Cancer Prev; 2003 Aug; 12(4):309-15. PubMed ID: 12883384
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
